In a filing, Biomarin Pharmaceutical Inc revealed its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $92618.0 on Mar 19 ’25. In the deal valued at $71.52 per share,1,295 shares were sold. As a result of this transaction, Burkhart Erin now holds 16,955 shares worth roughly $1.15 million.
Then, Burkhart Erin bought 1,295 shares, generating $92,618 in total proceeds.
Before that, Guyer Charles Greg sold 7,034 shares. Biomarin Pharmaceutical Inc shares valued at $501,355 were divested by the EVP, Chief Technical Officer at a price of $71.28 per share. As a result of the transaction, Guyer Charles Greg now holds 87,655 shares, worth roughly $5.96 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock fall -3.89% to $67.94. Over the last five days, the stock has lost -5.02%. Biomarin Pharmaceutical Inc shares have risen nearly 3.36% since the year began. Nevertheless, the stocks have fallen -22.21% over the past one year. While a 52-week high of $94.85 was reached on 03/07/25, a 52-week low of $60.63 was recorded on 01/16/25. SMA at 50 days reached $67.71, while 200 days put it at $73.34.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 66.97, which if violated will result in even more drops to 66.01. On the upside, there is a resistance level at 69.77. A further resistance level may holdings at 71.59. The Relative Strength Index (RSI) on the 14-day chart is 40.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.04%. Stochastics %K at 37.70% indicates the stock is a holding.
How much short interest is there in Biomarin Pharmaceutical Inc?
A steep rise in short interest was recorded in Biomarin Pharmaceutical Inc stocks on 2025-03-14, growing by 0.3 million shares to a total of 4.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.47 million shares. There was a rise of 6.32%, which implies that there is a positive sentiment for the stock.
